Cargando…

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats

Background: The Department of Health and Human Services reports that prescription pain reliever (e.g., oxycodone) misuse was initiated by 4,400 Americans each day in 2019. Amid the opioid crisis, effective strategies to prevent and treat prescription opioid use disorder (OUD) are pressing. In precli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Illenberger, Jessica M., Flores-Ramirez, Francisco J., Matzeu, Alessandra, Mason, Barbara J., Martin-Fardon, Rémi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172671/ https://www.ncbi.nlm.nih.gov/pubmed/37180716 http://dx.doi.org/10.3389/fphar.2023.1127735

Ejemplares similares

Alternative use of suvorexant (Belsomra(®)) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence
por: Flores-Ramirez, Francisco J., et al.
Publicado: (2022)

Blockade of Orexin Receptors in the Posterior Paraventricular Nucleus of the Thalamus Prevents Stress-Induced Reinstatement of Reward-Seeking Behavior in Rats With a History of Ethanol Dependence
por: Matzeu, Alessandra, et al.
Publicado: (2020)

Cocaine-Seeking Behavior Induced by Orexin A Administration in the Posterior Paraventricular Nucleus of the Thalamus Is Not Long-Lasting: Neuroadaptation of the Orexin System During Cocaine Abstinence
por: Matzeu, Alessandra, et al.
Publicado: (2021)

Targeting the Orexin System for Prescription Opioid Use Disorder
por: Matzeu, Alessandra, et al.
Publicado: (2020)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value
por: Matzeu, Alessandra, et al.
Publicado: (2022)

Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus
por: Matzeu, Alessandra, et al.
Publicado: (2018)

Blockade of corticotropin-releasing factor receptor 1 in the central amygdala prevents cocaine-seeking behaviour induced by orexin-A administered to the posterior paraventricular nucleus of the thalamus in male rats
por: Matzeu, Alessandra, et al.
Publicado: (2021)

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA(A) and Glutamate Receptors
por: Razavi, Bibi Marjan, et al.
Publicado: (2020)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

The paraventricular nucleus of the thalamus is recruited by both natural rewards and drugs of abuse: recent evidence of a pivotal role for orexin/hypocretin signaling in this thalamic nucleus in drug-seeking behavior
por: Matzeu, Alessandra, et al.
Publicado: (2014)

Effects of sex and estrous cycle on intravenous oxycodone self-administration and the reinstatement of oxycodone-seeking behavior in rats
por: Hinds, Nicole M., et al.
Publicado: (2023)

Effects of sex and estrous cycle on intravenous oxycodone self-administration and the reinstatement of oxycodone-seeking behavior in rats
por: Hinds, Nicole M., et al.
Publicado: (2023)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist
por: Coyner, Aaron S., et al.
Publicado: (2016)

Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit
por: Azimaraghi, Omid, et al.
Publicado: (2020)

Ranking the contribution of behavioral measures comprising oxycodone self-administration to reinstatement of drug-seeking in male and female rats
por: Guha, Suman K., et al.
Publicado: (2022)

Voluntary alcohol intake alters the motivation to seek intravenous oxycodone and neuronal activation during the reinstatement of oxycodone and sucrose seeking
por: Wilkinson, Courtney S., et al.
Publicado: (2023)

Voluntary alcohol intake alters the motivation to seek intravenous oxycodone and neuronal activation during the reinstatement of oxycodone and sucrose seeking
por: Wilkinson, Courtney S., et al.
Publicado: (2023)

Opiate anticipation, opiate induced anatomical changes in hypocretin (Hcrt, orexin) neurons and opiate induced microglial activation are blocked by the dual Hcrt receptor antagonist suvorexant, while opiate analgesia is maintained
por: McGregor, Ronald, et al.
Publicado: (2023)

Orexin/hypocretin (Orx/Hcrt) transmission and drug-seeking behavior: is the paraventricular nucleus of the thalamus (PVT) part of the drug seeking circuitry?
por: Martin-Fardon, Rémi, et al.
Publicado: (2012)

The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration
por: Srinivasan, Subhashini, et al.
Publicado: (2012)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Profile of suvorexant in the management of insomnia
por: Sutton, Eliza L
Publicado: (2015)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats
por: Pravetoni, Marco, et al.
Publicado: (2014)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant
por: Dietrich, Hendrik, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2ncv4e3i8va697tkdthl6f2a6f